Risk‐adapted bendamustine + rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real‐world report on 141 consecutive Swedish patients

Bendamustine + rituximab (BR) is the current first‐line standard‐of‐care for chronic lymphocytic leukaemia (CLL) in fit patients aged 66–70 years, whereas chlorambucil + CD20 antibody is recommended in older patients with co‐morbidities. This retrospective real‐world study investigated whether risk‐...

Descripción completa

Detalles Bibliográficos
Autores principales: Mattsson, Agnes, Sylvan, Sandra E., Asklid, Anna, Wiggh, Joel, Winqvist, Maria, Lundin, Jeanette, Mansouri, Larry, Rosenquist, Richard, Johansson, Hemming, Österborg, Anders, Hansson, Lotta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Haematological Malignancy ‐ Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689859/
https://www.ncbi.nlm.nih.gov/pubmed/32779190
http://dx.doi.org/10.1111/bjh.17032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689859/
https://www.ncbi.nlm.nih.gov/pubmed/32779190
http://dx.doi.org/10.1111/bjh.17032

Ejemplares similares